Sana Biotechnology (SANA) Common Equity (2020 - 2026)

Sana Biotechnology's Common Equity history runs 7 years deep, the most recent figure standing at $119.2 million for Q1 2026.

• In Q1 2026, Common Equity fell 42.97% year-over-year to $119.2 million; the TTM figure through Mar 2026 stood at $119.2 million (down 42.97% YoY), while the FY2025 annual figure was $160.9 million, down 35.78% from the prior year.
• Common Equity came in at $119.2 million for Q1 2026 at Sana Biotechnology, down from $160.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $701.7 million in Q1 2022 to a low of $119.2 million in Q1 2026.
• A 5-year average of $347.5 million and a median of $339.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slipped 4.33% in 2024 and tumbled 63.92% in 2025, its largest moves.
• Sana Biotechnology's Common Equity stood at $499.3 million in 2022, then slumped by 42.42% to $287.5 million in 2023, then fell by 12.87% to $250.5 million in 2024, then tumbled by 35.78% to $160.9 million in 2025, then retreated by 25.88% to $119.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $119.2 million, $160.9 million, and $195.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison